Irene Orlow, PhD

Attending Biologist

Irene Orlow, Associate Attending Biologist

Office Phone


Office Fax



University of Buenos Aires

Current Research Interests/Research Goals

Dr. Orlow leads the Molecular Epidemiology Laboratory. Her research interests include the study of host genetic and phenotypic characteristics in relation to cancer prognosis and survivorship in patients with melanoma, breast, and bladder cancer. In the area of melanoma, she is a member of the international Genes, Environment, and Melanoma (GEM) Study group, and the InterMEL consortium. Collaborations within GEM include among others, research on the vitamin D receptor and chemokine/chemokine receptor polymorphisms, and their role as modifiers of patients’ survival.  She collaborates with Dr. Halpern (Dermatology) and Dr. Satagopan (Biostatistics) in studies that evaluate the effect of genetics, phenotypic characteristics, and exposures to further the knowledge of the biology and epidemiology of nevi —a known risk factor for melanoma. With Dr. Ahles, she is assessing the impact of host genetics and other biomarkers on neurocognitive function in patients with breast cancer. She, Dr. Correa (Neurology ), and Dr. Satagopan (Biostatistics) are examining genetic characteristics in relation to cognitive function in patients treated with radiation. With Dr. Hay (Psychiatry & Behavioral Sciences), she is evaluating the personal utility of genomic testing among patients at risk to develop melanoma. With her lab, Dr. Orlow supports additional investigations from multiple disciplines in the study of human specimens in relation to cancer etiology, prognosis and survivorship. She oversees the National Colonoscopy Study biorepository, and the lab serves as biorepository for large epidemiologic studies including GEM, EDGE, CASH, and WECARE.


Selected peer-reviewed publications:

  1. Orlow I, Tommasi DV, Bloom B, Ostrovnaya I, Cotignola J, Mujumdar U, Busam KJ, Jungbluth AA, Scolyer RA, Thompson JF, Armstrong BK, Berwick M, Thomas NE, Begg CB. Evaluation of the clonal origin of multiple primary melanomas using molecular profiling. J Invest Dermatol, 129(8):1972-1982, 2009. PMC2745834

  2. Cotignola J, Chou JF, Roy P, Mitra N, Busam K, Halpern AC, and Orlow I. Investigation of the effect of MDM2 SNP309 and TP53 Arg72Pro polymorphisms on the age of onset of cutaneous melanoma. J Invest Dermatol 132:1471-1478, 2012. PMID:22336942

  3. Correa DD, Satagopan J, Baser RE, Cheung K, Richards E, Lin M, Karimi S, Lyo J, DeAngelis LM, Orlow I. Apolipoprotein E polymorphisms and cognitive functions in patients with brain tumors. Neurology 83:320-327, 2014. PMC4115606

  4. Gibbs DC, Orlow I, Bramson JI, Kanetsky PA, Luo L, Kricker A, Armstrong BK, Anton-Culver H, Gruber SB, Marrett LD, Gallagher RP, Zanetti R, Rosso S, Dwyer T, Sharma A, La Pilla E, From L, Busam KJ, Cust AE, Ollila DW, Begg CB, Berwick M, Thomas NE; GEM Study Group. Association of Interferon Regulatory Factor-4polymorphism rs12203592 with divergent melanoma pathways. J Natl Cancer Inst.108(7) 1-9, 2016. PMC4948568

  5. Orlow I, Reiner AS, Thomas NE, Roy P, Kanetsky PA, Luo L, Paine S, Armstrong BK, Kricker A, Marrett LD, Rosso S, Zanetti R, Gruber SB, Anton-Culver H, Gallagher RP, Dwyer T, Busam K, Begg CB, Berwick M; GEM Study Group. Vitamin D receptor polymorphisms and survival in patients with cutaneous melanoma: a population-based study. Carcinogenesis. 37(1):30-8, 2016. PMC4715233

For a complete list of publications: